The best antibiotic for mycoplasma depends on which species is causing your infection, but macrolides like azithromycin are the most widely recommended starting point, especially for respiratory infections. Mycoplasma bacteria lack a cell wall, which makes them naturally immune to common antibiotics like penicillin and amoxicillin. Only a few antibiotic classes work against them, and the right choice depends on whether you’re dealing with a lung infection (Mycoplasma pneumoniae) or a sexually transmitted infection (Mycoplasma genitalium).
Why Common Antibiotics Don’t Work
Most bacteria are surrounded by a rigid cell wall, and many popular antibiotics, including penicillins, cephalosporins, and similar drugs, kill bacteria by disrupting that wall. Mycoplasma species simply don’t have one. That means an entire category of antibiotics is useless against them from the start.
The antibiotics that do work target other parts of the organism. Macrolides (azithromycin, clarithromycin) and tetracyclines (doxycycline) shut down mycoplasma’s ability to build proteins by binding to its ribosomes. Fluoroquinolones (moxifloxacin, levofloxacin) take a different approach, blocking the enzymes mycoplasma needs to copy its DNA. These three classes form the core of mycoplasma treatment.
Best Antibiotics for Mycoplasma Pneumoniae
For the respiratory form of mycoplasma, which causes “walking pneumonia” and prolonged coughs, macrolides are generally considered the treatment of choice for both children and adults. Azithromycin is the most commonly prescribed because of its short course and mild side-effect profile. Symptoms typically start improving within two to three days of starting treatment.
Tetracyclines like doxycycline are a solid second-line option for older children and adults. Fluoroquinolones are reserved for adults when the first two classes aren’t suitable. The CDC recommends against using tetracyclines or fluoroquinolones in young children under normal circumstances, since tetracyclines can permanently stain developing teeth and fluoroquinolones carry a risk of cartilage damage in growing joints.
Macrolide resistance in M. pneumoniae has been a growing concern globally, though in the United States the rates remain relatively low. A 2024 study analyzing nearly 1,000 positive samples in U.S. children found macrolide-resistance mutations in about 2.4% of cases, with monthly rates peaking at 4.4%. In parts of East Asia, resistance rates have historically been much higher, which is why local resistance patterns matter when choosing treatment.
Best Antibiotics for Mycoplasma Genitalium
Treating M. genitalium, the sexually transmitted species, is more complicated. Unlike M. pneumoniae, this organism has developed significant resistance to multiple drug classes, and a single antibiotic often isn’t enough. Current CDC guidelines recommend a two-step sequential approach rather than a single prescription.
When resistance testing is available and shows the infection is sensitive to macrolides, the recommended regimen is doxycycline twice daily for seven days, followed by azithromycin for four more days (a larger initial dose on day one, then a smaller dose for three days). The doxycycline phase reduces the bacterial load before azithromycin delivers the finishing blow.
When resistance testing isn’t available, or the infection is confirmed macrolide-resistant, the CDC recommends doxycycline for seven days followed by moxifloxacin for seven days. This is the default approach when resistance status is unknown, because macrolide resistance in M. genitalium is common enough that azithromycin alone frequently fails. For pelvic inflammatory disease linked to M. genitalium, moxifloxacin alone for 14 days has been effective at clearing the organism.
Side Effects Across the Three Classes
Azithromycin and other macrolides are the gentlest option for most people. The most common side effects are gastrointestinal: nausea, diarrhea, and stomach cramps. These are usually mild and resolve quickly.
Doxycycline commonly causes sun sensitivity, so you burn more easily outdoors. It can also irritate the esophagus if you take it without enough water or lie down too soon afterward. Taking it with food helps. In children, tetracyclines can cause permanent tooth discoloration and temporarily slow bone growth, which is why they’re avoided in younger kids.
Fluoroquinolones like moxifloxacin carry the most serious risk profile. They’ve been linked to tendon damage (including rupture), nerve problems, and mood changes. A network meta-analysis published in The Lancet found that levofloxacin was associated with one of the highest rates of adverse reactions among children treated for mycoplasma pneumonia. These drugs are effective, but they’re intentionally kept as a later-line option because of these risks.
Antibiotic Choices for Children and Pregnancy
For children with mycoplasma pneumonia, macrolides are the clear first choice. Tetracyclines become an option for older children (typically eight and up), but fluoroquinolones are generally reserved for adults only. The CDC specifically advises considering the potential adverse effects in both children and pregnant women before using fluoroquinolones or tetracyclines.
Pregnancy narrows the options further. Tetracyclines are contraindicated because they affect fetal bone and tooth development. Fluoroquinolones are also avoided when possible. Azithromycin is typically the safest available choice for pregnant patients with mycoplasma infections, though treatment decisions for M. genitalium during pregnancy can be particularly challenging given the limited drug options and high resistance rates.
When Standard Treatment Fails
For M. pneumoniae, treatment failure is uncommon in the U.S. given the low macrolide resistance rates. Switching to doxycycline or a fluoroquinolone usually resolves the infection.
M. genitalium is a different story. Multiple cases of infections resistant to all standard therapies have emerged, prompting research into newer drugs. Lefamulin, an antibiotic from a class called pleuromutilins (already FDA-approved for community-acquired pneumonia), has shown excellent activity against multi-drug-resistant M. genitalium strains in lab testing. Clinical trials are underway evaluating it as a rescue treatment for people who have failed standard regimens or who can’t take moxifloxacin. It works by binding to the same part of the ribosome that macrolides target, but through a different mechanism that sidesteps existing resistance.
What to Expect During Treatment
Regardless of which antibiotic you’re prescribed, most people with mycoplasma pneumonia notice their symptoms fading within two to three days of starting treatment. A lingering cough can persist for a few weeks even after the infection clears, which is normal. For M. genitalium, because treatment courses are longer (often 11 to 14 days total with sequential therapy), it takes more time to know whether the regimen worked. A follow-up test is important, particularly for M. genitalium, to confirm the infection has been fully cleared.